The clinical spectrum of de novo donor-specific antibodies in pediatric renal transplant recipients

American Journal of Transplantation

Volumn 14, Issue 10, 2014, Pages 2350-2358

  Kim, J J ^a,b   Balasubramanian, R ^a   Michaelides, G ^c   Wittenhagen, P ^a   Sebire, N J ^a,d   Mamode, N ^a,b   Shaw, O ^e   Vaughan, R ^e   Marks, S D ^a,d  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

^c UNIVERSITY OF LONDON   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e GUY S HOSPITAL   (United Kingdom)

Author keywords

Alloantibody; clinical research; dysfunctionl rejection: antibody mediated (ABMR); kidney (allograft) function; kidney transplantation; nephrology; pediatrics; practice; rejection: chronic; rejection: vascular

Indexed keywords

AZATHIOPRINE; HLA ANTIBODY; HLA B ANTIBODY; HLA C ANTIBODY; HLA DPB ANTIBODY; HLA DQ ANTIGEN; HLA DQA ANTIBODY; HLA DQB ANTIBODY; HLA DR ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS; UNCLASSIFIED DRUG; ALLOANTIGEN;

ARTICLE; CHILD; COHORT ANALYSIS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FLUORESCENCE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HUMAN; HUMAN TISSUE; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; KIDNEY TUBULE DISORDER; MAJOR CLINICAL STUDY; MALE; PEDIATRIC SURGERY; PROSPECTIVE STUDY; RETINA BLOOD VESSEL; VASCULITIS; ADOLESCENT; BLOOD; DONOR; PRESCHOOL CHILD;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; ISOANTIGENS; KIDNEY TRANSPLANTATION; MALE; PROSPECTIVE STUDIES; TISSUE DONORS;

EID: 84908219105     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12859     Document Type: Article

References (46)

1. Lamb KE, Lodhi S, Meier-Kriesche HU., Long-term renal allograft survival in the United States: A critical reappraisal. Am J Transplant 2011; 11: 450-462.
2. Loupy A, Hill GS, Jordan SC., The impact of donor-specific anti-HLA antibodies on late kidney allograft failure. Nat Rev Nephrol 2012; 8: 348-357.
3. Wiebe C, Nickerson P., Posttransplant monitoring of de novo human leukocyte antigen donor-specific antibodies in kidney transplantation. Curr Opin Organ Transplant 2013; 18: 470-477.
4. Tait BD, Susal C, Gebel HM, et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation 2013; 95: 19-47.
5. Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant 2012; 12: 1157-1167.
6. Cooper JE, Gralla J, Chan L, Wiseman AC., Clinical significance of post kidney transplant de novo DSA in otherwise stable grafts. Clin Transpl 2011; 359-364.
7. Banasik M, Boratynska M, Koscielska-Kasprzak K, et al. The impact of de novo donor-specific anti-human leukocyte antigen antibodies on 5-year renal transplant outcome. Transplant Proc 2013; 45: 1449-1452.
8. Smet J, Mascart F, Schandene L., Are the reference values of B cell subpopulations used in adults for classification of common variable immunodeficiencies appropriate for children? Clin Immunol 2011; 138: 266-273.
9. Xanthakis V, Sullivan LM, Vasan RS., Multilevel modeling versus cross-sectional analysis for assessing the longitudinal tracking of cardiovascular risk factors over time. Stat Med 2013; 32: 5028-5038.
10. Schwartz GJ, Munoz A, Schneider MF, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol 2009; 20: 629-637.
11. Kausman JY, Patel B, Marks SD., Standard dosing of tacrolimus leads to overexposure in pediatric renal transplantation recipients. Pediatr Transplant 2008; 12: 329-335.
12. Sis B, Mengel M, Haas M, et al. Banff '09 meeting report: Antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 2010; 10: 464-471.
13. R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2013, 3.01 ed.
14. Jose Pinheiro DB, DebRoy S, Sarkar S, et al. nlme: Linear and nonlinear mixed effects models. R package. 3.1-111 ed. 2013.
15. Lefaucheur C, Loupy A, Vernerey D, et al. Antibody-mediated vascular rejection of kidney allografts: A population-based study. Lancet 2013; 381: 313-319.
16. Wuhl E, Trivelli A, Picca S, et al. Strict blood-pressure control and progression of renal failure in children. N Engl J Med 2009; 361: 1639-1650.
17. Mengel M, Sis B, Haas M, et al. Banff 2011 meeting report: New concepts in antibody-mediated rejection. Am J Transplant 2012; 12: 563-570.
18. Sis B, Jhangri GS, Riopel J, et al. A new diagnostic algorithm for antibody-mediated microcirculation inflammation in kidney transplants. Am J Transplant 2012; 12: 1168-1179.
19. Haas M, Sis B, Racusen LC, et al. Banff 2013 meeting report: Inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant 2014; 14: 272-283.
20. Hidalgo LG, Campbell PM, Sis B, et al. De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure. Am J Transplant 2009; 9: 2532-2541.
21. de Kort H, Willicombe M, Brookes P, et al. Microcirculation inflammation associates with outcome in renal transplant patients with de novo donor-specific antibodies. Am J Transplant 2013; 13: 485-492.
22. Zarkhin V, Kambham N, Li L, et al. Characterization of intra-graft B cells during renal allograft rejection. Kidney Int 2008; 74: 664-673.
23. Muorah MR, Brogan PA, Sebire NJ, Trompeter RS, Marks SD., Dense B cell infiltrates in paediatric renal transplant biopsies are predictive of allograft loss. Pediatr Transplant 2009; 13: 217-222.
24. Cooper JE, Gralla J, Cagle L, Goldberg R, Chan L, Wiseman AC., Inferior kidney allograft outcomes in patients with de novo donor-specific antibodies are due to acute rejection episodes. Transplantation 2011; 91: 1103-1109.
25. Lynch RJ, Silva IA, Chen BJ, Punch JD, Cascalho M, Platt JL., Cryptic B cell response to renal transplantation. Am J Transplant 2013; 13: 1713-1723.
26. Platt JL, Cascalho M., Donor specific antibodies after transplantation. Pediatr Transplant 2011; 15: 686-690.
27. Valenzuela NM, Reed EF., The link between major histocompatibility complex antibodies and cell proliferation. Transplant Rev (Orlando) 2011; 25: 154-166.
28. Terasaki PI, Cai J., Human leukocyte antigen antibodies and chronic rejection: From association to causation. Transplantation 2008; 86: 377-383.
29. Ginevri F, Nocera A, Comoli P, et al. Posttransplant de novo donor-specific HLA antibodies identify pediatric kidney recipients at risk for late antibody-mediated rejection. Am J Transplant 2012; 12: 3355-3362.
30. Chaudhuri A, Ozawa M, Everly MJ, et al. The clinical impact of humoral immunity in pediatric renal transplantation. J Am Soc Nephrol 2013; 24: 655-664.
31. Miettinen J, Peräsaari J, Lauronen J, et al. Donor-specific HLA antibodies and graft function in children after renal transplantation. Pediatr Nephrol 2012; 27: 1011-1019.
32. Willicombe M, Roufosse C, Brookes P, et al. Acute cellular rejection: Impact of donor-specific antibodies and C4d. Transplant J 2014; 97: 433-439.
33. Sellares J, de Freitas DG, Mengel M, et al. Understanding the causes of kidney transplant failure: The dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 2012; 12: 388-399.
34. DeVos JM, Gaber AO, Knight RJ, et al. Donor-specific HLA-DQ antibodies may contribute to poor graft outcome after renal transplantation. Kidney Int 2012; 82: 598-604.
35. Freitas MC, Rebellato LM, Ozawa M, et al. The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes. Transplantation 2013; 95: 1113-1119.
36. Willicombe M, Brookes P, Sergeant R, et al. De novo DQ donor-specific antibodies are associated with a significant risk of antibody-mediated rejection and transplant glomerulopathy. Transplantation 2012; 94: 172-177.
37. Tambur AR, Leventhal JR, Zitzner JR, Walsh RC, Friedewald JJ., The DQ barrier: Improving organ allocation equity using HLA-DQ information. Transplantation 2013; 95: 635-640.
38. Tambur AR, Leventhal JR, Friedewald JJ, Ramon DS., The complexity of human leukocyte antigen (HLA)-DQ antibodies and its effect on virtual crossmatching. Transplantation 2010; 90: 1117-1124.
39. Tambur AR, Leventhal JR, Walsh RC, Zitzner JR, Friedewald JJ., HLA-DQ barrier: Effects on cPRA calculations. Transplantation 2013; 96: 1065-1072.
40. Magee BA, Martin J, Cole MP, Morris KG, Courtney AE., Effects of HLA-matched blood transfusion for patients awaiting renal transplantation. Transplantation 2012; 94: 1111-1116.
41. Brown CC, Sebire NJ, Wittenhagen P, Shaw O, Marks SD., Clinical significance of isolated v lesions in paediatric renal transplant biopsies: Muscular arteries required to refute the diagnosis of acute rejection. Transplant Int 2014; 27: 170-175.
42. Sigdel TK, Li L, Tran TQ, et al. Non-HLA antibodies to immunogenic epitopes predict the evolution of chronic renal allograft injury. J Am Soc Nephrol 2012; 23: 750-763.
43. Taniguchi M, Rebellato LM, Cai J, et al. Higher risk of kidney graft failure in the presence of anti-angiotensin II type-1 receptor antibodies. Am J Transplant 2013; 13: 2577-2589.
44. Loupy A, Lefaucheur C, Vernerey D, et al. Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med 2013; 369: 1215-1226.
45. Reed EF, Rao P, Zhang Z, et al. Comprehensive assessment and standardization of solid phase multiplex-bead arrays for the detection of antibodies to HLA. Am J Transplant 2013; 13: 1859-1870.
46. UK Clinical Research Network. A randomized controlled clinical trial to determine if a combined screening/treatment programme can prevent premature failure of renal transplants due to chronic rejection in patients with HLA antibodies. Available at: http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=13990. Accessed October 25, 2013.